The lack of potent Ras and c-Myc inhibitors and the acquirement of drug resistance make ERK3, ERK4, and MK5 attractive targets for therapeutic drugs in tumours with perturbed RAS, RAF or c-MYC activity. The gene discussed is MYC; the disease is neoplasm.